Yttrium-90 Radioembolization for Unresectable, Chemoresistant Breast Cancer Liver Metastases: A Large Single-Center Experience of 40 Patients
- 15 December 2013
- journal article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 21 (4), 1296-1303
- https://doi.org/10.1245/s10434-013-3436-1
Abstract
There are a paucity of data on the treatment of unresectable, chemoresistant breast cancer liver metastases (BRCLM) with yttrium-90 (Y90) radioembolization. Forty patients underwent resin-based Y90 radioembolization for unresectable, chemoresistant BRCLM between 2006 and 2012 in a single institution. All patients were followed up with imaging studies at regular intervals as clinically indicated until death. Radiologic response was evaluated with the Response Criteria in Solid Tumors criteria. Clinical toxicities were prospectively recorded as per the National Cancer Institute Common Toxicity Criteria. Survival was calculated by the Kaplan–Meier method and potential prognostic variables were identified on univariate and multivariate analysis. Follow-up was complete in all patients. The median follow-up was 11.2 (range 0.6–30.5) months and the median survival after Y90 radioembolization was 13.6 months, with a 24-month survival of 39 %. On imaging follow-up of 38 patients who survived beyond 1 month of treatment, a complete response (CR) to treatment was observed in two patients (5 %), partial response (PR) in 10 patients (26 %), stable disease (SD) in 15 patients (39 %), and progressive disease (PD) in 11 patients (29 %). Two factors were associated with an improved survival on multivariate analysis: CR/PR to treatment (vs. SD vs. PD; p p = 0.004). Sixteen patients (40 %) developed clinical toxicity after treatment; all complications were minor grade I/II and resolved without active intervention. This study provides supportive evidence of the safety and efficacy on Y90 radioembolization for the treatment of unresectable, chemoresistant BRCLM. Further prospective investigation is required to assess the suitability of this treatment in this population.Keywords
This publication has 26 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- 18F-FDG PET/CT Predicts Survival After Radioembolization of Hepatic Metastases from Breast CancerJournal of Nuclear Medicine, 2012
- Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicinBreast Cancer Research and Treatment, 2011
- Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastasesZeitschrift für Krebsforschung und Klinische Onkologie, 2010
- Factors Predicting Response and Survival After Yttrium-90 Radioembolization of Unresectable Neuroendocrine Tumor Liver MetastasesAnnals of Surgery, 2010
- Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liverCancer, 2007
- Is Liver Resection Justified for Patients With Hepatic Metastases From Breast Cancer?Annals of Surgery, 2006
- Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysisJNCI Journal of the National Cancer Institute, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- The regional treatment of liver metastases from breast cancerJournal of Surgical Oncology, 1994